Table 1.

Patient characteristics.

		Number	%
Median age (range)		53 (25–73)
Sex	Female	31	77.5
	Male	9	22.5
Performance status (ECOG)	0	8	20
	1	30	75
	2	2	5
Malignancy type	Breast	19	47.5
	Ovary	7	17.5
	Pancreas	3	7.5
	Lung cancer: non-small cell	2	5
	Other*	9	22.5
Prior therapy	Chemotherapy	40	100
	Hormone therapy	14	35
	Immunotherapy	8	20
	Radiotherapy	24	60
	PARP inhibitor**	8	20
	Prior platinum	32	80
	Other systemic therapy	11	27.5
	Other therapy	5	12.5
Number of prior lines of therapy	1	4	10
	2	4	10
	3	11	27.5
	≥4	21	52.5
Number of prior chemotherapy regimens–neoadjuvant	1	7	17.5
	2	1	2.5
Number of prior chemotherapy regimens–adjuvant	1	14	35
	2	1	2.5
Number of prior chemotherapy regimens–advanced/metastatic disease	1	9	22.5
	2	11	27.5
	3	9	22.5
	≥4	8	20
Mutation Status (known at study enrollment)	Germline BRCA1	6	15
	Germline BRCA2***	13	33
	Somatic BRCA1 or 2	3	8
	PALB2 ***	1	2.5

Forty patients were enrolled and treated in the study.

*Other tumor type includes one of each: adrenal, anal, appendix, biliary, colon, head and neck, small intestine, soft tissue sarcoma, and uterine sarcoma.

**Includes one patient treated on the blinded trial of PARP inhibitor (niraparib vs placebo) and not unblinded.

***Two additional pts had BRCA2 VUS and 1 pt PALB2VUS.